Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin, Ju-Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R. Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger

Blood (2016) 127 (12): 1551–1558.

https://doi.org/10.1182/blood-2015-07-657403

Published: 2016

Includes: Supplemental data

Journal Articles

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F. Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2599.

https://doi.org/10.1182/blood.V124.21.2599.2599

Published: 2014

Journal Articles

DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia

Blood (2014) 124 (21): 365.

https://doi.org/10.1182/blood.V124.21.365.365

Published: 2014

Journal Articles

Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression

Lili Chen, PhD, Wei Chen, PhD, Maria Mysliwski, Justin Serio, James Ropa, Fardokht Abulwerdi, Rebecca J. Chan, MD PhD, Jay P. Patel, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Ari M Melnick, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Zaneta Nikolovska-Coleska, PhD, Andrew G. Muntean, PhD

Blood (2014) 124 (21): 3565.

https://doi.org/10.1182/blood.V124.21.3565.3565

Published: 2014

Journal Articles

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Elisabeth M. Paietta, PhD, Janis Racevskis, PhD, Hugo F Fernandez, MD, Ju-Whei Lee, PhD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Jay P. Patel, Mithat Gönen, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Elihu H. Estey, MD

Blood (2014) 124 (21): 941.

https://doi.org/10.1182/blood.V124.21.941.941

Published: 2014

Journal Articles

Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities

Chezi Ganzel, MD, Zhuoxin Sun, PhD, Mithat Gonen, Jay P. Patel, Omar Abdel-Wahab, MD, Hugo F Fernandez, MD, Jacob M. Rowe, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Elisabeth M. Paietta, PhD

Blood (2014) 124 (21): 1016.

https://doi.org/10.1182/blood.V124.21.1016.1016

Published: 2014

Journal Articles

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 373.

https://doi.org/10.1182/blood.V124.21.373.373

Published: 2014

Journal Articles

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

Raajit Rampal, Fatima Al-Shahrour, Omar Abdel-Wahab, Jay P. Patel, Jean-Philippe Brunel, Craig H. Mermel, Adam J. Bass, Jennifer Pretz, Jihae Ahn, Todd Hricik, Outi Kilpivaara, Martha Wadleigh, Lambert Busque, D. Gary Gilliland, Todd R. Golub, Benjamin L. Ebert, Ross L. Levine

Blood (2014) 123 (22): e123–e133.

https://doi.org/10.1182/blood-2014-02-554634

Published: 2014

Includes: Supplemental data

Journal Articles

Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia

Blood (2013) 122 (21): 2499.

https://doi.org/10.1182/blood.V122.21.2499.2499

Published: 2013

Journal Articles

Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms

Raajit K. Rampal, M.D., Ph.D., Sean M. Devlin, PhD, Jay P. Patel, Kristina M. Knapp, BS, Minal Patel, Joel R Greenbowe, BS, Lauren E Young, MS, Jie He, PhD, Kai Wang, MD PhD, Michelle K. Nahas, PhD, Roman Yelensky, PhD, Geoff A. Otto, PhD, Doron Lipson, PhD, Philip J. Stephens, PhD, Vincent A. Miller, MD, Ross L. Levine, MD

Blood (2013) 122 (21): 1588.

https://doi.org/10.1182/blood.V122.21.1588.1588

Published: 2013

Journal Articles

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

Blood (2013) 121 (24): 4917–4924.

https://doi.org/10.1182/blood-2013-03-493197

Published: 2013

Includes: Supplemental data

Journal Articles

Serum 2-Hydroxyglutarate Levels Predict Isocitrate Dehydrogenase Mutations and Clinical Outcome in Acute Myeloid Leukemia.

Courtney D. DiNardo, MD, Ross L. Levine, Kathleen J Propert, ScD, Alison W. Loren, MD, Elisabeth Paietta, PhD, Zhouxin Sun, PhD, Kimberly Straley, BS, Katharine Yen, Jay P. Patel, Samuel Agresta, MD, Omar Abdel-Wahab, Alexander E Perl, MD, Hugo F Fernandez, MD, David Margolis, MD, MSCE, Martin S. Tallman, MD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 2481.

https://doi.org/10.1182/blood.V120.21.2481.2481

Published: 2012

Journal Articles

Conditional Deletion of Asxl1 Results in Myelodysplasia

Omar Abdel-Wahab, M.D., Jie Gao, PhD, Mazhar Adli, PhD, Young Rock Chung, MSc, Richard Koche, PhD, Alan H. Shih, MD, PhD, Suveg Pandey, BSc, Lindsay M. La-Fave, PhD, Delphine Ndiaye-Lobry, Yu Sup Shin, BSc, Parva K. Bhatt, BSc, Jay P. Patel, Xinyang Zhao, PhD, Christopher Y. Park, MD, PhD, Jacob D. Jaffe, PhD, Bradley E. Bernstein, MD, PhD, Iannis Aifantis, PhD, Ross L. Levine

Blood (2012) 120 (21): 308.

https://doi.org/10.1182/blood.V120.21.308.308

Published: 2012

Journal Articles

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Mithat Gönen, Zhuoxin Sun, Maria E. Figueroa, Jay P. Patel, Omar Abdel-Wahab, Janis Racevskis, Rhett P. Ketterling, Hugo Fernandez, Jacob M. Rowe, Martin S. Tallman, Ari Melnick, Ross L. Levine, Elisabeth Paietta

Blood (2012) 120 (11): 2297–2306.

https://doi.org/10.1182/blood-2012-02-414425

Published: 2012

Includes: Supplemental data

Journal Articles

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Blood (2010) 116 (21): 851.

https://doi.org/10.1182/blood.V116.21.851.851

Published: 2010

NARROW

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia

Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia

Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

Serum 2-Hydroxyglutarate Levels Predict Isocitrate Dehydrogenase Mutations and Clinical Outcome in Acute Myeloid Leukemia.

Conditional Deletion of Asxl1 Results in Myelodysplasia

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only